

**Clinical Practice Recommendations on Indication and T  
Transplantation in Mature T Cell and NK/T Cell Lympho  
Effort on Behalf of the Guidelines Committee of the Am  
Marrow Transplantation**

Biology of Blood and Marrow Transplantation

23, 1826-1838

DOI: [10.1016/j.bbmt.2017.07.027](https://doi.org/10.1016/j.bbmt.2017.07.027)

Citation Report

#	ARTICLE	IF	CITATIONS
1	NK/T Cell Lymphoma: Updates in Therapy. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 7-12.	1.2	32
2	Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. <i>Annals of Oncology</i> , 2018, 29, 715-723.	0.6	110
3	Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. <i>Blood</i> , 2018, 132, 245-253.	0.6	52
4	Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2018, 131, 2528-2540.	0.6	155
5	The role of allogeneic stem cell transplantation in T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2018, 30, 301-307.	1.1	5
6	Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas. <i>Cancer Management and Research</i> , 2018, Volume 10, 6731-6742.	0.9	7
7	Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 315-321.	0.7	32
8	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
9	Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1508-1517.	2.0	112
10	Hematopoietic stem cell transplantation for T-cell lymphoma. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e6.	0.6	2
11	Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing. <i>Bone Marrow Transplantation</i> , 2019, 54, 159-163.	1.3	2
12	The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2595-2604.	1.2	12
13	Allogenic Transplant for Non-Hodgkin Lymphoma. , 2019, , 209-229.		0
14	Overview of Cutaneous T-Cell Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 669-686.	0.9	8
15	Management of NK/T-Cell Lymphoma, Nasal Type. <i>Journal of Oncology Practice</i> , 2019, 15, 513-520.	2.5	48
16	Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma. <i>Frontiers in Microbiology</i> , 2019, 10, 2235.	1.5	26
17	JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL). <i>International Journal of Hematology</i> , 2019, 109, 137-140.	0.7	7
18	Treatment and prognosis of mature (non-â€œanaplastic) T-â€œand NK-â€œcell lymphomas in childhood, adolescents, and young adults. <i>British Journal of Haematology</i> , 2019, 185, 1086-1098.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Extranodal NK-/T-Cell Lymphomas and EBV+ Lymphoproliferative Diseases of Childhood. , 2019, , 271-279.		0
20	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1â€Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1695-1700.	2.0	14
21	Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 386.	1.3	19
22	Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?. <i>Current Oncology Reports</i> , 2019, 21, 65.	1.8	2
23	First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. <i>Annals of Hematology</i> , 2019, 98, 1961-1972.	0.8	23
24	The impact of early diagnosis on the prognosis of extranodal NK/T-cell lymphoma with massive lung involvement: a case report. <i>BMC Pulmonary Medicine</i> , 2019, 19, 48.	0.8	3
25	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL). <i>International Journal of Hematology</i> , 2019, 109, 371-376.	0.7	7
26	A survey of the therapeutic landscape in peripheral T-cell lymphomas: the importance of expert hematopathology review in the era of targeted therapies and precision medicine. <i>Annals of Lymphoma</i> , 2019, 3, 9-9.	4.5	1
27	New/Revised Entities in Gastrointestinal Lymphoproliferative Disorders. <i>Surgical Pathology Clinics</i> , 2019, 12, 733-743.	0.7	2
28	Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALKâ€positive anaplastic largeâ€cell lymphoma refractory to chemotherapy and brentuximab vedotin. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2500-2504.	0.2	6
29	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1237-1244.	1.3	5
30	T-Cell and NK-Cell Lymphomas. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	0
31	Transplantation. <i>Cancer Treatment and Research</i> , 2019, 176, 269-287.	0.2	2
32	Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2019, 109, 175-186.	0.7	14
33	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 6.	6.9	29
35	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 76-82.	2.0	26
36	Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 796-803.	1.3	9
37	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	2.0	43

#	ARTICLE	IF	CITATIONS
38	Controversies in the Treatment of Peripheral Tâ€cell Lymphoma. HemaSphere, 2020, 4, e461.	1.2	5
39	Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34<sup>+</sup> cells is associated with improved survival. Leukemia and Lymphoma, 2020, 61, 3027-3029.	0.6	1
41	Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group. Biology of Blood and Marrow Transplantation, 2020, 26, 2346-2358.	2.0	4
42	Successful treatment of hepatosplenic T cell lymphoma in an adolescent with Turner syndrome using ifosfamide, carboplatin, and etoposide followed by allogeneic hematopoietic stem cell transplant. Pediatric Blood and Cancer, 2020, 67, e28528.	0.8	3
43	Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma. Cancers, 2020, 12, 3125.	1.7	6
44	Primary adrenal extranodal NK/T-cell lymphoma: A case report and literature review. Leukemia Research Reports, 2020, 14, 100223.	0.2	2
46	Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis. Leukemia and Lymphoma, 2020, 61, 3306-3318.	0.6	3
47	Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study. Annals of Hematology, 2020, 99, 2801-2809.	0.8	4
48	Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). Journal of Hematology and Oncology, 2020, 13, 56.	6.9	31
49	Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature. Diagnostics, 2020, 10, 341.	1.3	8
50	Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma. Current Hematologic Malignancy Reports, 2020, 15, 316-332.	1.2	11
51	Improved outcomes with allogeneic compared with autologous stem cell transplantation in aggressive Tâ€cell lymphoma. European Journal of Haematology, 2020, 105, 514-516.	1.1	2
52	Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report. Journal of Medical Case Reports, 2020, 14, 43.	0.4	3
53	Primary cutaneous anaplastic large cell lymphoma with rapid liver infiltration after spontaneous resolution of the primary lesion. Journal of Dermatology, 2020, 47, e190-e191.	0.6	1
54	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 1247-1256.	2.0	139
55	Sensitive Photodynamic Detection of Adult T-cell Leukemia/Lymphoma and Specific Leukemic Cell Death Induced by Photodynamic Therapy: Current Status in Hematopoietic Malignancies. Cancers, 2020, 12, 335.	1.7	9
56	Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and S�zary syndrome. Hematological Oncology, 2020, 38, 266-271.	0.8	14
57	Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. International Journal of Hematology, 2020, 112, 74-83.	0.7	6

#	ARTICLE	IF	CITATIONS
58	Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry. <i>Annals of Hematology</i> , 2021, 100, 157-165.	0.8	2
59	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 57.e1-57.e8.	0.6	7
60	Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 323-329.	0.6	2
61	Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan. <i>Leukemia and Lymphoma</i> , 2021, 62, 819-827.	0.6	3
62	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 106-112.e1.	0.2	9
63	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. <i>Bone Marrow Transplantation</i> , 2021, 56, 786-797.	1.3	5
64	Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas. <i>Clinical Hematology International</i> , 2021, 3, 72.	0.7	3
65	HSCT in Malignancies. <i>Organ and Tissue Transplantation</i> , 2021, , 99-114.	0.0	0
66	Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas. <i>Cell Transplantation</i> , 2021, 30, 096368972199961.	1.2	1
67	CCR4-positive peripheral T-cell lymphoma presenting as eosinophilic pneumonia and developing from prolonged pustular psoriasis. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199616.	0.4	2
68	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. <i>Journal of Clinical Oncology</i> , 2021, 39, 487-498.	0.8	27
70	Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group. <i>Frontiers in Oncology</i> , 2020, 10, 583050.	1.3	12
71	Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 493.e1-493.e8.	0.6	5
72	Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. <i>Seminars in Hematology</i> , 2021, 58, 85-94.	1.8	4
73	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-cell lymphoma, nasal type: A French study from the Soci�t� Francophone de Greffe de Moelle et de Transplantation Cellulaire (SFGM-TC). <i>American Journal of Hematology</i> , 2021, 96, 834-845.	2.0	5
74	Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. <i>Advances in Therapy</i> , 2021, 38, 3789-3802.	1.3	3
75	Primary Gastrointestinal T/NK Cell Lymphoma. <i>Cancers</i> , 2021, 13, 2679.	1.7	7
76	Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 388-388.	0.6	4

#	ARTICLE	IF	CITATIONS
77	What's new in peripheral T-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 52-60.	0.8	4
78	Advances in Frontline Management of Peripheral T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 368-378.	0.2	0
79	Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma. <i>Turkish Journal of Haematology</i> , 2021, 38, 126-137.	0.2	5
80	Extranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein-Barr Virus Relation. <i>Microorganisms</i> , 2021, 9, 1381.	1.6	11
81	How to Sequence Therapies in Peripheral T Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 74.	1.3	4
82	Hematopoietic Stem Cell Transplantation in T Cell and Natural Killer Cell Lymphomas: Update on Recent Advances. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 571-588.	0.6	3
83	Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Soci�t� Francophone de Greffe de Moelle et de Therapie Cellulaire. <i>Bone Marrow Transplantation</i> , 2021, 56, 2849-2856.	1.3	2
84	Allogeneic Transplant Overview and Matched Related Donor Transplant. <i>Organ and Tissue Transplantation</i> , 2021, , 187-221.	0.0	0
85	Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. <i>F1000Research</i> , 2020, 9, 1091.	0.8	8
86	Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 3122-3129.	0.3	3
87	Extranodal NK/T cell lymphoma. <i>Blood Research</i> , 2020, 55, S63-S71.	0.5	20
88	HSCT in Malignancies. <i>Organ and Tissue Transplantation</i> , 2020, , 1-16.	0.0	0
89	Allogeneic Transplant Overview and Matched Related Donor Transplant. <i>Organ and Tissue Transplantation</i> , 2020, , 1-34.	0.0	0
90	Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance. <i>Internal Medicine Journal</i> , 2021, , .	0.5	1
93	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	2.5	16
95	Progress of Hematopoietic Stem Cell Transplantation and Radiotherapy in the Treatment of Extranodal NK/T Cell Lymphoma. <i>Frontiers in Oncology</i> , 2022, 12, 832428.	1.3	3
96	Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome. <i>Frontiers in Oncology</i> , 2021, 11, 749691.	1.3	0
97	Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis. <i>Leukemia and Lymphoma</i> , 2022, 63, 855-864.	0.6	3

#	ARTICLE	IF	CITATIONS
101	Real Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T Cell Lymphomas: A Multicenter Study of Turkish Hematology Research and Education Group (Threg). Turkish Journal of Haematology, 0, , .	0.2	0
102	Long-term Survival Following EPOCH Therapy with Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Peripheral T-cell Lymphoma: A report of Three Cases. Journal of Illusion, 2022, 11, 187-192.	0.0	0
103	V. Recent Progress of Diagnosis and Treatment for Peripheral T-cell Lymphoma. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 1418-1425.	0.0	0
104	The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3449-3459.	1.2	1
105	Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients. Scientific Reports, 2022, 12, .	1.6	2
106	Management of Peripheral T-cell Lymphomas and the Role of Transplant. Current Oncology Reports, 2022, 24, 1489-1499.	1.8	4
107	EXABS-185-TCL The Next Rational Therapeutic Regimen in Newly Diagnosed PTCL. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S85-S86.	0.2	0
109	An unusual case of lymphoma â€” a case of extranodal NK/T-cell lymphoma, nasal type. The Egyptian Journal of Otolaryngology, 2022, 38, .	0.1	0
111	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source. Transplantation and Cellular Therapy, 2023, 29, 267.e1-267.e5.	0.6	2
112	Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas. Cancers, 2023, 15, 220.	1.7	0
113	Upâ€”front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extraâ€”nodal <scp>NKT</scp> cell lymphoma: A multicenter realâ€”world study in China. European Journal of Haematology, 2023, 110, 680-687.	1.1	2
120	Hematopoietic Cell Transplantation in Rare Hematologic Malignancies. , 2024, , 383-394.		0
121	Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. , 2024, , 341-355.		0
122	Hepatosplenic T-cell lymphoma with hemophagocytic lymphohistiocytosis, revealed by fever of unknown origin. Memo - Magazine of European Medical Oncology, 0, , .	0.3	0
125	Stem Cell Transplant for T Cell Non-Hodgkin Lymphoma. , 2023, , 335-364.		0
126	Indications for Allogeneic Stem Cell Transplant. , 2023, , 399-410.		0